Aldeyra The (ALDX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.36 (-1.45%), Market cap $0.10B, 52-week low–high $1.24 ~ $5.89.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, includi
Financial statements, price targets, institutional (13F) holdings and related news for Aldeyra The are updated in real time on BlackAll Trade.
Aldeyra The trades at $1.36 (-1.45%). Real-time quotes and charts are available on BlackAll Trade.
Aldeyra The has a market cap of about $0.10B.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species